Guangyong Peng, Zhiwu Zeng, Yinbiao Qiao, Wengui Ma, Kun Zhao, Xiaoting Zhang, Xu Zhang*, Jianhui Li* and Yaxian Mo*
Volume5-Issue3
Dates: Received: 2024-02-17 | Accepted: 2024-03-17 | Published: 2024-03-23
Pages: 236-241
Abstract
Hepatoid Adenocarcinoma of the Stomach (HAS) is a rare unique subtype of Gastric Cancer (GC) with a low incidence but a high mortality rate. We report a female case of 67-years-old with APF producing hepatoid adenocarcinoma of the gastric antrum with liver and lung metastases. Abdominal CT of the patient showed multiple liver masses, which were considered as metastatic tumors and proved to be adenocarcinoma by pathological examination of a biopsy. The gastroscopy revealed antral ulcer complicated with bleeding. The biopsy results of hepatoid adenocarcinoma were consistent with the results of liver masses. Moreover, α-Fetoprotein (AFP) increased sharply to 86332 ng/mL. Thus, the diagnosis of gastric hepatoid adenocarcinoma with liver metastasis was established. In terms of treatment, liver TACE embolization was performed first, followed by radical gastrectomy and resection of liver tumor. During the operation, multiple small tumors (less than 5cm in diameter) in the liver were treated by radiofrequency ablation. The patient recovered well after surgery, with a rapid decline in AFP. Postoperative CT indicated the presence of bioactive tumors in the liver and new tumors in the lung. Lung puncture pathology suggests tumor metastasis. Liver and lung were treated with radiofrequency ablation and SOX (Oxaliplatin and Tegacil) chemotherapy. There was no significant recurrence 20 months after surgery, and personalized systematic treatment for this patient was effective. Standard treatment for gastric hepatoid adenocarcinoma has not yet been established, and personalized systematic therapy is the preferred treatment.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1888
Certificate of Publication
Copyright
© 2024 Peng G, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Peng G, Zeng Z, Qiao Y, Ma W, Zhao K, Zhang X, Zhang X, Li J, Mo Y. Hepatoid Adenocarcinoma of the Stomach with Liver and Pulmonary Metastases: A Case Report and Literature Review. J Biomed Res Environ Sci. 2024 Mar 23; 5(3): 236-241. doi: 10.37871/jbres1888, Article ID: JBRES1888, Available at: https://www.jelsciences.com/articles/jbres1888.pdf
Subject area(s)
References
- Li M, Mei YX, Wen JH, Jiao YR, Pan QR, Kong XX, et al. Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics. Cancer Lett. 2023;559:216104. Epub 20230301. doi: 10.1016/j.canlet.2023.216104. PubMed PMID: 36863507.
- Liu Q, Bannan M, Melamed J, Witkin GB, Nonaka D. Two cases of hepatoid adenocarcinoma of the intestine in association with inflammatory bowel disease. Histopathology. 2007;51(1):123-5. Epub 20070526. doi: 10.1111/j.1365-2559.2007.02715.x. PubMed PMID: 17532770.
- Kashani A, Ellis JC, Kahn M, Jamil LH. Liver metastasis from hepatoid adenocarcinoma of the esophagus mimicking hepatocellular carcinoma. Gastroenterol Rep (Oxf). 2017;5(1):67-71. Epub 20150620. doi: 10.1093/gastro/gov021. PubMed PMID: 26094198; PubMed Central PMCID: PMCPMC5444241.
- Xia R, Zhou Y, Wang Y, Yuan J, Ma X. Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments. Front Oncol. 2021;11:633916. Epub 20210412. doi: 10.3389/fonc.2021.633916. PubMed PMID: 33912455; PubMed Central PMCID: PMCPMC8071951.
- Lu J, Ding Y, Chen Y, Jiang J, Chen Y, Huang Y, et al. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. Nat Commun. 2021;12(1):3946. Epub 20210624. doi: 10.1038/s41467-021-24170-0. PubMed PMID: 34168152; PubMed Central PMCID: PMCPMC8225795.
- Zhu M, Chen E, Yu S, Xu C, Yu Y, Cao X, et al. Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach. Cancer Commun (Lond). 2022;42(10):1032-5. Epub 20220719. doi: 10.1002/cac2.12336. PubMed PMID: 35851588; PubMed Central PMCID: PMCPMC9558685.
- Zou M, Li Y, Dai Y, Sun L, Huang T, Yuan X, et al. AFP-producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review. Onco Targets Ther. 2019;12:7649-54. Epub 20190918. doi: 10.2147/OTT.S216501. PubMed PMID: 31571915; PubMed Central PMCID: PMCPMC6756369.
- Yang X, Wang A, Li J, Zhou K, Ji K, Ji X, et al. Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS). BMC Cancer. 2023;23(1):53. Epub 20230116. doi: 10.1186/s12885-023-10516-y. PubMed PMID: 36647059; PubMed Central PMCID: PMCPMC9841701.
- Gong W, Su Y, Liu A, Liu J, Sun D, Jiang T, et al. Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma. Neoplasma. 2018;65(3):326-30. doi: 10.4149/neo_2018_170207N84. PubMed PMID: 29788728.
- Yang Q, Liu Y, Zhang S. Hepatoid adenocarcinoma of the stomach: CT findings. Front Oncol. 2023;13:1036763. Epub 20230203. doi: 10.3389/fonc.2023.1036763. PubMed PMID: 36816961; PubMed Central PMCID: PMCPMC9937653.
- Yuan J, Wang G, Liu M, Gong Z. MRI features of hepatic metastasis from hepatoid adenocarcinoma of the stomach: A case report. Radiol Case Rep. 2022;17(7):2295-8. Epub 20220505. doi: 10.1016/j.radcr.2022.04.011. PubMed PMID: 35570866; PubMed Central PMCID: PMCPMC9092068.
- Han L, Ding N, Li L, Wei X, Hu J, Liu B, et al. Hepatoid adenocarcinoma of the duodenal papilla with hepatic metastases: A case report and literature review. Front Oncol. 2022;12:948892. Epub 20220808. doi: 10.3389/fonc.2022.948892. PubMed PMID: 36003790; PubMed Central PMCID: PMCPMC9393733.
- Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19(6):1146-53. Epub 20080227. doi: 10.1093/annonc/mdn026. PubMed PMID: 18304963.
- Lin JX, Wang ZK, Hong QQ, Zhang P, Zhang ZZ, He L, et al. Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach. JAMA Netw Open. 2021;4(10):e2128217. Epub 20211001. doi: 10.1001/jamanetworkopen.2021.28217. PubMed PMID: 34609494; PubMed Central PMCID: PMCPMC8493440.
- Wei J, Ji K, Zhang Y, Zhang J, Wu X, Ji X, et al. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach. Cell Oncol (Dordr). 2023. Epub 20231109. doi: 10.1007/s13402-023-00892-9. PubMed PMID: 37943484.
